沙利度胺联合GP方案治疗晚期三阴性乳腺癌的临床疗效及不良反应分析  

Clinical efficacy and adverse reactions analysis of thalidomide combined with GP regimen in the treatment of advanced triple-negative breast cancer

作　　者：李红姬[1] 金载勇[1] LI Hong-ji;JIN Zai-yong(Jilin Central Hospital,Jilin 132011,China)

机构地区：[1]吉林市中心医院,132011

出　　处：《中国实用医药》2018年第32期95-96,共2页China Practical Medicine

摘　　要：目的探讨沙利度胺联合GP方案治疗晚期三阴性乳腺癌的临床疗效及不良反应。方法 90例晚期三阴性乳腺癌患者,根据治疗方法不同分为对照组和观察组,每组45例。对照组患者给予GP方案治疗,观察组患者给予沙利度胺联合GP方案治疗。比较两组患者总缓解率,中位生存时间,治疗前后患者肿瘤标志物百分率、癌症患者生命质量测定量表(EORTC-C30)评分,不良反应发生情况。结果观察组患者总缓解率为68.89%,高于对照组的44.44%,差异具有统计学意义(P<0.05)。治疗前,两组患者肿瘤标志物百分率、EORTC-C30评分比较差异无统计学意义(P>0.05);治疗后,观察组患者肿瘤标志物百分率、EORTC-C30评分均优于对照组,差异具有统计学意义(P<0.05)。观察组中位生存时间长于对照组。观察组患者胃肠道反应发生率为22.22%,显著低于对照组的46.67%,差异具有统计学意义(P<0.05)。结论沙利度胺联合GP方案治疗晚期三阴性乳腺癌的应用效果确切,可有效降低肿瘤标志物,改善生存质量,延长生存时间,减轻不良反应,值得推广应用。Objective To discuss the clinical efficacy and adverse reactions of thalidomide combined with GP regimen in the treatment of advanced triple-negative breast cancer. Methods A total of 90 patients with advanced triple-negative breast cancer were divided by different treatment methods into control group and observation group, with 45 cases in each group. The control group received GP regimen, and the observation group received thalidomide combined with GP regimen. Comparison were made on total remission rate, media survival time, percentage of tumor markers before and after treatment, European Organization for Research and Treatment of Cancer（EORTC-C30） score before and after treatment, and occurrence of adverse reactions between the two groups. Results The observation group had higher total remission rate as 68.89% than 44.44% in the control group, and the difference was statistically significant（P〈0.05）. Before treatment, both groups had no statistically significant difference in percentage of tumor markers and EORTC-C30 score（P〈0.05）. After treatment, the observation group had better percentage of tumor markers and EORTC-C30 score than the control group, and the difference was statistically significant（P〈0.05）. The observation group had longer media survival time than the control group, and the difference was statistically significant（P〈0.05）. The observation group had obviously lower incidence of gastrointestinal reaction as 22.22% than 46.67% in the control group, and the difference was statistically significant（P〈0.05）. Conclusion Combination of thalidomide and GP regimen shows affirmed application effect in treating advanced triple-negative breast cancer, and it can effectively reduce tumor markers, improve quality of life, prolong survival time, relieve adverse reactions. So it is worthy of popularization and application.

关 键 词：沙利度胺 GP方案 晚期三阴性乳腺癌 临床疗效 不良反应 

分 类 号：R737.9[医药卫生—肿瘤]